brand logo

Am Fam Physician. 2021;103(6):337-343

Related letter: Reevaluating the Measurement of Potency of Topical Corticosteroids

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Topical corticosteroids are an essential tool for treating inflammatory skin conditions such as psoriasis and atopic dermatitis. Topical corticosteroids are classified by strength and the risk of adverse effects such as atrophy, striae, rosacea, telangiectasias, purpura, and other cutaneous and systemic reactions. The risk of adverse effects increases with prolonged use, a large area of application, higher potency, occlusion, and application to areas of thinner skin such as the face and genitals. When prescribing topical corticosteroids for use in children, lower potencies and shorter durations should be used. Topical corticosteroids can work safely and effectively in patients who are pregnant or lactating. They are available in formulations such as ointments, creams, lotions, gels, foams, oils, solutions, and shampoos. The quantity of corticosteroid prescribed depends on the duration of treatment, the frequency of application, the skin location, and the total surface area treated. Correct patient application is critical to successful use. Patients may be taught application using the fingertip unit method. One fingertip unit is the amount of medication dispensed from the tip of the index finger to the crease of the distal interphalangeal joint and covers approximately 2% body surface area on an adult. Topical corticosteroids are applied once or twice per day for up to three weeks for super-high-potency corticosteroids or up to 12 weeks for high- or medium-potency corticosteroids. There is no specified time limit for low-potency topical corticosteroid use.

Effective treatment of dermatologic disorders depends on an accurate diagnosis based on history, physical examination, and appropriate diagnostic tests such as biopsy or skin scraping. Typical characteristics of skin diseases amenable to treatment with topical corticosteroids include inflammation, hyperproliferation, and immunologic etiology.

Topical corticosteroids are approved by the U.S. Food and Drug Administration for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.1 Table 1 lists skin conditions that respond to treatment with topical corticosteroids.2 This article discusses the use of topical corticosteroids on nonmucosal surfaces.

High-potency steroids (groups I and II)
Alopecia areata
Atopic dermatitis (resistant)
Bullous pemphigoid
Discoid lupus
Dyshidrotic eczema
Hyperkeratotic eczema
Labial adhesion
Lichen planus
Lichen sclerosus (skin)
Lichen simplex chronicus
Nummular eczema
Poison ivy (severe)
Medium-potency steroids (groups III, IV, and V)
Anal inflammation (severe)
Asteatotic eczema
Atopic dermatitis
Dermatitis (severe)
Infantile acropustulosis
Intertrigo (severe, short term)
Lichen sclerosus (vulva)
Nummular eczema
Scabies (after scabicide)
Seborrheic dermatitis
Stasis dermatitis
Low-potency steroids (groups VI and VII)
Dermatitis (diaper)
Dermatitis (eyelids)
Dermatitis (face)
Perianal inflammation

Despite widespread use of topical corticosteroids, high-quality research demonstrating their effectiveness exists for a relatively small number of diagnoses. Multiple systematic reviews support the use of medium- and high-potency topical corticosteroids for the treatment of atopic dermatitis, and intermittent use to prevent a recurrence.3 A Cochrane review found evidence to support the use of topical corticosteroids for the treatment of psoriasis, with super-high-potency corticosteroids being the most effective.4

A limited number of double-blind, randomized controlled trials also support topical corticosteroid use for the treatment of lichen sclerosus,5 alopecia areata,6 vitiligo,7 bullous pemphigoid,8 phimosis,9 and aphthous ulcers.10 Lower-level evidence supports topical corticosteroid use for other conditions, including melasma,11 infantile acropustulosis,12 and prepubertal labial adhesions.13


The strength of a topical corticosteroid is a factor of the agent and concentration. Certain compounds are inherently more potent than others, and potency increases as the concentration of corticosteroid increases.

Topical corticosteroids are grouped into seven classes based on their performance on the vasoconstriction assay, which tests the ability of the corticosteroid to blanch skin. Many can fall into multiple classes based on their concentration. Evidence from small, nonrandomized trials supports the correlation between strength that is measured by the vasoconstriction assay and clinical effectiveness or risk of harm.14 The effectiveness of the corticosteroid may differ depending on the thickness of application, the condition being treated, duration of treatment, and if the medication is a brand name vs. generic formulation.15,16

Although it is not practical to memorize an exhaustive list of corticosteroids, clinicians should be well-acquainted with at least one in each of the low-, medium-, high-, and super-high-potency classes (Table 21,1719 ). This is sufficient to treat most corticosteroid-responsive skin conditions that present in primary care. Low-potency corticosteroids are useful in children or for mild, widespread disease, or on thin skin areas such as the face and groin. Medium- to high-potency corticosteroids are used for most areas on the body, such as the trunk and extremities. Super-high-potency corticosteroids are useful for severe disease and in areas of thick skin such as the palms, soles, or psoriatic lesions. Except in rare circumstances and for short durations, super-high-potency corticosteroids should not be used in children, under occlusion, or on the face, groin, or skinfolds.

Class (potency)AgentFormulationsMaximum duration*
I (super high)Betamethasone dipropionate augmented 0.05%Ointment, lotion, gel3 weeks
Clobetasol propionate 0.05%Ointment, cream, lotion, gel, foam, solution, shampoo, spray
Fluocinonide 0.1%Cream
Flurandrenolide 4 mcg per cm2 Tape
Halobetasol propionate 0.05%Ointment, cream
II (high)Amcinonide 0.1%Ointment, cream12 weeks
Betamethasone dipropionate 0.05%Ointment
Betamethasone dipropionate augmented 0.05%Cream
Desoximetasone 0.25%Ointment, cream
Desoximetasone 0.05%Gel
Diflorasone diacetate 0.05%Ointment
Fluocinonide 0.05%Ointment, cream, gel, solution
Halcinonide 0.1%Ointment, cream, solution
III, IV, V (medium)Amcinonide 0.1%Lotion12 weeks
Betamethasone dipropionate 0.05%Cream, lotion
Betamethasone valerate 0.12%Foam
Betamethasone valerate 0.1%Ointment, cream, lotion
Diflorasone diacetate 0.05%Cream
Fluocinolone acetonide 0.025%Ointment, cream
Flurandrenolide 0.05%Ointment, cream, lotion
Fluticasone propionate 0.05%Cream, lotion
Fluticasone propionate 0.005%Ointment
Hydrocortisone butyrate 0.1%Ointment, cream, lotion, solution
Hydrocortisone valerate 0.2%Ointment, cream
Mometasone furoate 0.1%Ointment, cream, lotion, solution
Triamcinolone acetonide 0.5%Ointment, cream
Triamcinolone acetonide 0.1%Ointment, cream, lotion
Triamcinolone acetonide 0.147 mg per gSpray
VI, VII (low)Alclometasone dipropionate 0.05%Ointment, creamNo specified limit
Desonide 0.05%Ointment, cream, lotion, gel, foam
Fluocinolone acetonide 0.01%Cream, solution, oil
Hydrocortisone 1%Ointment, cream, lotion, spray
Hydrocortisone 2.5%Ointment, cream, lotion, solution
Triamcinolone acetonide 0.025%Ointment, cream, lotion

Adverse Effects

Topical corticosteroids may cause cutaneous and systemic adverse effects (Table 320 ). A larger area of application and higher potency of corticosteroid increases the risk of adverse effects. The use of lower-potency corticosteroids and reduction in application frequency can significantly decrease the risk of adverse effects. Thin skin (e.g., the face, intertriginous areas) and the skin of children are more susceptible to adverse effects.17

Already a member/subscriber?  Log In


From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.